Lexicon's Phase 2b PROGRESS Study For DPNP Treatment Achieves Objectives, Stock Tanks In Pre-Market

(RTTNews) - Lexicon Pharmaceuticals, Inc. (LXRX), Monday announced topline results from the PROGRESS Phase 2b study evaluating pilavapadin in adult patients with moderate to severe diabetic peripheral neuropathic pain or DPNP.

The study achieved its objective with 10 mg dose exhibiting meaningful pain reduction and improved tolerability compared to that observed in the previous Phase 2 RELIEF-DPN-1 study.

During the study, all pilavapadin treatment arms demonstrated a reduction of 1.74 in the mean average daily pain score compared to the placebo.

Meanwhile, adverse events were more frequent in the pilavapadin treatment arms, but were significantly improved from the RELIEF-DPN-1 study across all doses.

Based on these findings, the company intends to advance into Phase 3 clinical development for DPNP.

In the pre-market hours, Lexicon's stock is tumbling 50.55 percent, to $0.34 on the Nasdaq.